ClinicalTrials.gg
Not yet recruitingNCT07945041Updated Nov 18, 2026

Optimizing Acute Care Rehabilitation for Critically Ill Adults

An interventional study of Rehabilitation Intervention in ICU Acquired Muscle Weakness, Critical Illness and Functional Impairment, sponsored by University of Colorado, Denver. Not yet recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to determine the optimal frequency, duration, and timing of physical therapy (PT) and occupational therapy (OT) rehabilitation to improve physical and cognitive function in critically ill adults receiving mechanical ventilation in the intensive care unit (ICU).

The main questions it aims to answer are:

  1. What combination of rehabilitation session frequency, session duration, and timing of OT initiation produces the greatest improvements in physical function and activities of daily living at hospital discharge and 3 months?
  2. Which patient characteristics, including age and comorbidities, are associated with greater benefits from different rehabilitation approaches?

Researchers will compare eight combinations of rehabilitation strategies, varying three components:

Session frequency: 4 versus 7 days per week. Session duration: 20 versus 40 minutes per session. Timing of OT initiation: Early initiation (within 24 hours of randomization) versus delayed initiation (at ICU discharge or 7 days after randomization, whichever occurs later).

Participants will:

  • Be randomly assigned to one of eight rehabilitation combinations.
  • Receive individualized, progressive PT focused on strength, balance, mobility, and endurance, beginning within 24 hours of randomization.
  • Receive individualized OT focused on daily activities, including grooming, bathing, dressing, and feeding, beginning according to their assigned group.
  • Participate in rehabilitation sessions until hospital discharge, 21 days after randomization, or successful completion of predefined rehabilitation milestones, whichever occurs first.
  • Undergo assessments of physical function, daily activities, and cognitive function during hospitalization and at hospital discharge.
  • Complete a follow-up assessment 3 months after hospital discharge to evaluate physical and cognitive function, quality of life, mental health, and recovery.
Read the detailed description

Survivors of critical illness frequently experience persistent physical and cognitive impairments that limit functional independence and quality of life. Intensive care unit (ICU)-acquired weakness is a major contributor to poor recovery, and prolonged bed rest can further accelerate muscle weakness and functional decline. Although ICU-initiated rehabilitation delivered by physical therapists (PTs) and occupational therapists (OTs) has demonstrated benefits, considerable uncertainty remains regarding the optimal frequency and duration of rehabilitation sessions and the appropriate timing of OT initiation.

This multicenter randomized clinical trial will use the Multiphase Optimization Strategy (MOST) framework to systematically evaluate and optimize the delivery of ICU-initiated rehabilitation. The study will employ a 2×2×2 factorial design to assess the individual and combined effects of three rehabilitation components: session frequency, session duration, and timing of OT initiation. The trial will enroll 360 critically ill adults receiving mechanical ventilation across participating academic medical centers.

The rehabilitation intervention consists of established PT and OT approaches delivered through a standardized, individualized, and progressive framework. PT will target strength, balance, mobility, and endurance, while OT will focus on activities of daily living, including grooming, bathing, dressing, and feeding. Rehabilitation activities will be tailored to each participant's functional capabilities and clinical condition, with progression guided by predefined performance milestones. Both interventions are also designed to engage cognitive processes through task repetition, sequencing, cueing, and problem-solving.

The study will evaluate the effects of different rehabilitation combinations on physical function, performance of daily activities, and cognition during hospitalization and at 3-month follow-up. Additional assessments will characterize recovery across domains including muscle strength, mobility, exercise capacity, cognitive function, health-related quality of life, mental health, and healthcare utilization.

In addition to determining the most effective combination of rehabilitation components, the study will examine whether patient-level characteristics, particularly age and comorbidity burden, are associated with differences in treatment response. Using a hybrid efficacy-implementation approach, quantitative and qualitative findings will inform optimization based on effectiveness, affordability, scalability, and efficiency.

The overall objective is to identify an evidence-based, resource-conscious rehabilitation strategy that maximizes functional recovery following critical illness and is suitable for evaluation in a subsequent clinical trial and eventual implementation in routine clinical practice.

02

Conditions studied

  • ICU Acquired Muscle Weakness
  • Critical Illness
  • Functional Impairment
  • Rehabilitation After Critical Illness

Browse trials for

Keywords

  • ICU-acquired muscle weakness
  • Rehavilitation after critical illness
  • critical illness
03

In context

Critical Illness

1,786 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's planned enrollment of 360 is above the median of 90 across 930 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,545 studies on the registry; 319 are open to participants now.

Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ICU patients age >18 years.
  • Mechanically ventilated for \<48 hours.
  • Expected to require mechanical ventilation for >24 hours at the time of randomization.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing functional impairment defined as a Barthel score \<70.
  • Pre-existing cognitive impairment using an IQCODE cutoff of 3.42.
  • Acute brain pathology (e.g., traumatic brain injury, stroke) without exclusion for ICU-delirium.
  • Proven or suspected spinal cord injury or neuromuscular disease that will result in permanent or prolonged weakness (without exclusion for ICU-acquired weakness) at time of eligibility.
  • Has "bedrest" orders and/or non-weight bearing orders for lower limbs at time of eligibility.
  • \<180 days due to chronic medical condition (per judgement of clinical team).
  • Limitation in use of life support (excluding a sole "No CPR/DNR" order) at time of eligibility.
  • Death deemed inevitable due to severity of critical illness at time of eligibility (per clinical team).
  • Unable to understand/communicate in English.
  • Not the first ICU admission during the index hospital admission.
  • More than 72 hours since meeting all eligibility (to allow potential for early intervention).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Low Frequency / Short Duration / Delayed Occupational Therapy (OT)

    Participants will receive physical therapy (PT) and occupational therapy (OT) rehabilitation 4 days per week, with 20-minute sessions. PT will begin within 24 hours of randomization. OT will begin at ICU discharge or 7 days after randomization, whichever occurs later.

    Other: Rehabilitation Intervention

  • Experimental
    Low Frequency / Short Duration / Early Occupational Therapy (OT)

    Participants will receive physical therapy (PT) and occupational therapy (OT) rehabilitation 4 days per week, with 20-minute sessions. Both PT and OT will begin within 24 hours of randomization.

    Other: Rehabilitation Intervention

  • Experimental
    Low Frequency / Long Duration / Delayed Occupational Therapy (OT)

    Participants will receive physical therapy (PT) and occupational therapy (OT) rehabilitation 4 days per week, with 40-minute sessions. PT will begin within 24 hours of randomization. OT will begin at ICU discharge or 7 days after randomization, whichever occurs later.

    Other: Rehabilitation Intervention

  • Experimental
    Low Frequency / Long Duration / Early Occupational Therapy (OT)

    Participants will receive physical therapy (PT) and occupational therapy (OT) rehabilitation 4 days per week, with 40-minute sessions. Both PT and OT will begin within 24 hours of randomization.

    Other: Rehabilitation Intervention

  • Experimental
    High Frequency / Short Duration / Delayed Occupational Therapy (OT)

    Participants will receive PT and OT rehabilitation 7 days per week, with 20-minute sessions. PT will begin within 24 hours of randomization. OT will begin at ICU discharge or 7 days after randomization, whichever occurs later.

    Other: Rehabilitation Intervention

  • Experimental
    High Frequency / Short Duration / Early Occupational Therapy (OT)

    Participants will receive PT and OT rehabilitation 7 days per week, with 20-minute sessions. Both PT and OT will begin within 24 hours of randomization.

    Other: Rehabilitation Intervention

  • Experimental
    High Frequency / Long Duration / Delayed Occupational Therapy (OT)

    Participants will receive PT and OT rehabilitation 7 days per week, with 40-minute sessions. PT will begin within 24 hours of randomization. OT will begin at ICU discharge or 7 days after randomization, whichever occurs later.

    Other: Rehabilitation Intervention

  • Experimental
    High Frequency / Long Duration / Early Occupational Therapy (OT)

    Participants will receive PT and OT rehabilitation 7 days per week, with 40-minute sessions. Both PT and OT will begin within 24 hours of randomization.

    Other: Rehabilitation Intervention

Interventions

  • OtherRehabilitation Intervention

    The rehabilitation intervention consists of individualized, structured, and progressive physical therapy (PT) and occupational therapy (OT) delivered independently by licensed therapists. PT focuses on strength, balance, mobility, and endurance, while OT targets activities of daily living, including grooming, bathing, dressing, and feeding. Activities are tailored to participants' functional capabilities and progressed according to predefined performance criteria. Rehabilitation continues until the earliest of 21 days after randomization, hospital discharge, or successful completion of Level 4 of the rehabilitation program for two consecutive sessions.

06

What researchers measure

Primary outcomes

  1. Short Physical Performance Battery (SPPB) Score

    Lower extremity physical function will be assessed using the Short Physical Performance Battery (SPPB), which includes standing balance, repeated chair stands, and gait speed. Total scores range from 0 to 12, with higher scores indicating better physical performance.

    Time frame: Day of hospital discharge, up to 1 year.

  2. Activity Measure for Post-Acute Care (AM-PAC) Daily Activity Score

    Ability to perform activities of daily living will be assessed using the AM-PAC Daily Activity Inpatient Short Form. The instrument measures functional performance in daily activities, including upper extremity function. Scores are reported using a standardized scoring system, with a range from 6 to 24, with higher scores indicating better functional performance.

    Time frame: Day of hospital discharge, up to 1 year.

Secondary outcomes

  1. Medical Research Council (MRC) Sum-Score

    Upper and lower extremity muscle strength will be evaluated by standardized manual muscle testing using the Medical Research Council (MRC) sum-scale. Sacel ranges from 0 to 60, with higher scores indicating better global muscle strength.

    Time frame: Day of hospital discharge, up to 1 year.

  2. Handgrip Strength

    Muscle strength will be assessed using grip dynamometry of the dominant hand.

    Time frame: through study completion, an average of 1 year

  3. Nine-Hole Peg Test

    Upper extremity motor dexterity will be evaluated using the Nine-Hole Peg Test, which assesses performance of a standardized manual dexterity task by timing how long it takes the participant to complete the task.

    Time frame: through study completion, an average of 1 year

  4. Johns Hopkins Highest Level of Mobility (JH-HLM) Score

    Patient mobility will be assessed using the one-item Johns Hopkins Highest Level of Mobility scale, which evaluates the highest level of mobility achieved. Scale ranges from 0 to 8, with higher scores indicating better mobility.

    Time frame: Starting at Baseline (Day 0), daily assessments, through study completion, an average of 1 year

  5. Functional Status Score for the ICU (FSS-ICU)

    Functional mobility will be assessed using the FSS-ICU, which evaluates five tasks: rolling, supine-to-sit transfer, sitting at the edge of the bed, sit-to-stand transfer, and walking. The scale ranges from 0 to 35 points, with higher scores indicating better physical functioning and greater independence.

    Time frame: Starting at Baseline (Day 0), daily assessments, through study completion, an average of 1 year

  6. Activity Measure for Post-Acute Care (AM-PAC) Short Forms

    Functional mobility will be assessed using the Activity Measure for Post-Acute Care (AM-PAC) Mobility Short Form, which ranges from 6 to 24, with higher scores indicating better functional performance. Applied cognitive functioning will be assessed using the Activity Measure for Post-Acute Care (AM-PAC) Applied Cognition Short Form, which ranges from 0 to 39, with higher scores indicating better cognitive functional performance.

    Time frame: Daily assessments, through study completion, an average of 1 year

  7. Six-Minute Walk Test (6MWT) Distance

    Functional exercise capacity will be assessed using the Six-Minute Walk Test, which measures the distance walked during a six-minute period. The greater the distance the better functional exercise capacity, higher aerobic endurance, and improved overall mobility or cardiopulmonary function.

    Time frame: On day of hospital discharge, up to 1 year.

Other outcomes

  1. Montreal Cognitive Assessment (MoCA) Score

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a standardized screening instrument for cognitive impairment. The assessment ranges from 0 to 30, where higher scores indicate better cognitive function and a lower level of impairment.

    Time frame: On day of hospital discharge, and up to 1 year.

  2. Richmond Agitation-Sedation Scale (RASS) Score

    Sedation and agitation status will be evaluated using the Richmond Agitation-Sedation Scale (RASS). Ranges from -5 to +4, with higher scores indicating increasing levels of agitation, hyperactivity, or combativeness.

    Time frame: Daily during hospitalization, from Day 0 until hospital discharge, up to 1 year.

  3. Confusion Assessment Method for the ICU (CAM-ICU)

    Delirium status in the ICU will be assessed using the Confusion Assessment Method for the ICU (CAM-ICU). The scale ranges from 0 to 7, with higher scores indicating greater severity of delirium.

    Time frame: Daily during hospitalization, from Day 0 until hospital discharge, up to 1 year.

  4. Survival Status

    Survival status will be determined through medical record review during hospitalization and telephone follow-up at 3 months.

    Time frame: through study completion, an average of 1 year

  5. Duration of Mechanical Ventilation

    Total duration of mechanical ventilation during the index hospitalization will be determined through medical record review.

    Time frame: Daily during hospitalization, on the day of hospital discharge, up to 1 year.

  6. Intensive Care Unit (ICU) and Hospital Length of Stay

    Length of stay in the intensive care unit during and hospital length of stay in the index hospitalization will be determined through medical record review.

    Time frame: Daily during hospitalization, on the day of hospital discharge, up to 1 year.

  7. Hospital Discharge Location

    Discharge destination, including home or a rehabilitation facility, will be determined through medical record review.

    Time frame: day of hospital discharge, up to 1 year.

  8. Health-Related Quality of Life (EQ-5D-5L)

    Health-related quality of life will be assessed using the five-level EuroQol five-dimension questionnaire (EQ-5D-5L). Ranges from 0 to 1, with higher scores indicating better health-related quality of life (1 represents full/perfect health; 0 represents death).

    Time frame: 3 months after hospital discharge, up to 1 year.

  9. Hospital Anxiety and Depression Scale (HADS) Score

    Symptoms of anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). The total score range is from 0 to 42, with higher scors indicating greater severity of anxiety or depressive symptoms.

    Time frame: 3 months after hospital discharge, up to 1 year.

  10. Impact of Event Scale-6 (IES-6) Score

    Symptoms of post-traumatic stress will be assessed using the six-item Impact of Event Scale (IES-6). Scores range from 0 to 18, with elevated scores pointing toward a greater probability of clinically relevant posttraumatic stress disorder or significant trauma-related impact.

    Time frame: 3 months after hospital discharge, up to 1 year.

  11. Clinical Frailty Scale Score

    Frailty will be assessed using the Clinical Frailty Scale, the scale ranges from 1 to 9, with higher scores indicating a greater degree of functional dependence, vulnerability, and physiological decline

    Time frame: 3 months after hospital discharge, up to 1 year.

  12. Modified Medical Research Council Dyspnea (mMRC) Score

    Pulmonary symptoms will be assessed using the one-item Modified Medical Research Council Dyspnea scale. The scale ranges from 0 to 4, with higher scores indicating greater severity of breathlessness and functional disability.

    Time frame: 3 months after hospital discharge, up to 1 year.

  13. Self-Reported Recovery Scale

    Self-perceived overall recovery following critical illness will be assessed using the one-item Recovery Scale from an established core outcome set, where the highest number indicates completely recovered.

    Time frame: 3 months after hospital discharge, up to 1 year.

  14. Health Care Utilization

    Health care utilization, including admissions to hospitals, skilled nursing facilities, and rehabilitation facilities, will be assessed using a telephone survey supplemented by medical record review.

    Time frame: 3 months after hospital discharge, up to 1 year.

  15. Days Alive and Out of Hospital

    Days alive and out of hospital will be calculated using information collected through the Health Care Utilization Survey.

    Time frame: 3 months after hospital discharge, up to 1 year.

07

Study locations

4 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2030, 43 months later.

Of 404 non-industry interventional studies with no phase under Critical Illness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 43 months is above that.

Counting every sponsor, half of 408 studies reached it within 21 months; a quarter within 11 and three quarters within 40.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 18, 2026
StartEst.
Dec 2026
Primary completionEst.
Jul 2030
CompletionEst.
Aug 31, 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07945041
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jul 2030 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

Jeffrey McKeehan, AC-AGNP
Contact
jeffrey.mckeehan@cuanschutz.edu
303-724-6080
Rafaela Mantelli, MD
Contact
303-724-0961
Marc Moss, MD
principal investigator · University of Colorado, Department of Pulmonary, Allergy and Critical Care Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion